Expression of TGFβ-1 and EHD1 correlated with survival of non-small cell Lung cancer

详细信息    查看全文

• 作者：Yuanyuan Gao ; Yan Wang ; Lichun Sun ; Qingwei Meng ; Li Cai ; Xiaoqun Dong
• 关键词：TGFβ ; 1 ; EHD1 ; Survival ; Non ; small cell lung cancer (NSCLC)
• 刊名：Tumor Biology
• 出版年：2014
• 出版时间：September 2014
• 年：2014
• 卷：35
• 期：9
• 页码：9371-9380
• 全文大小：1,675 KB
• 参考文献：1. Yang Y, Dong J, Sun K, Zhao L, Zhao F, Wang L, et al. Obesity and incidence of lung cancer: a meta-analysis. Int J Cancer J Int du Cancer. 2013;132(5):1162-. doi:10.1002/ijc.27719 . CrossRef
  2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: Cancer J Clin. 2011;61(2):69-0. doi:10.3322/caac.20107 .
  3. Walker J, Sawhney A, Hansen CH, Symeonides S, Martin P, Murray G, et al. Treatment of depression in people with lung cancer: a systematic review. Lung Cancer. 2013;79(1):46-3. doi:10.1016/j.lungcan.2012.09.014 . CrossRef
  4. Scott WJ, Howington J, Feigenberg S, Movsas B, Pisters K. American College of Chest P. Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132(3):234S-2S. doi:10.1378/chest.07-1378 . CrossRef
  5. Anderson CS, Curran WJ. Combined modality therapy for stage III non-small-cell lung cancer. Semin Radiat Oncol. 2010;20(3):186-1. doi:10.1016/j.semradonc.2010.01.007 . CrossRef
  6. Price KA, Azzoli CG, Gaspar LE. Chemoradiation for unresectable stage III non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2008;20(3):204-. doi:10.1053/j.semtcvs.2008.09.007 . CrossRef
  7. Gorsch SM, Memoli VA, Stukel TA, Gold LI, Arrick BA. Immunohistochemical staining for transforming growth factor beta 1 associates with disease progression in human breast cancer. Cancer Res. 1992;52(24):6949-2.
  8. Jasani B, Wyllie FS, Wright PA, Lemoine NR, Williams ED, Wynford-Thomas D. Immunocytochemically detectable TGF-beta associated with malignancy in thyroid epithelial neoplasia. Growth Factors (Chur, Switzerland). 1990;2(2-3):149-5. CrossRef
  9. Massague J, Blain SW, Lo RS. TGFbeta signaling in growth control, cancer, and heritable disorders. Cell. 2000;103(2):295-09. CrossRef
  10. Jeon HS, Jen J. TGF-beta signaling and the role of inhibitory Smads in non-small cell lung cancer. J Thorac Oncol: Off Publication Int Assoc Study Lung Cancer. 2010;5(4):417-. doi:10.1097/JTO.0b013e3181ce3afd . CrossRef
  11. Yin M, Soikkeli J, Jahkola T, Virolainen S, Saksela O, Holtta E. TGF-beta signaling, activated stromal fibroblasts, and cysteine cathepsins B and L drive the invasive growth of human melanoma cells. Am J Pathol. 2012;181(6):2202-6. doi:10.1016/j.ajpath.2012.08.027 . CrossRef
  12. Zaiman AL, Podowski M, Medicherla S, Gordy K, Xu F, Zhen L, et al. Role of the TGF-beta/Alk5 signaling pathway in monocrotaline-induced pulmonary hypertension. Am J Respir Crit Care Med. 2008;177(8):896-05. doi:10.1164/rccm.200707-1083OC . CrossRef
  13. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer. 2003;3(11):807-1. doi:10.1038/nrc1208 . CrossRef
  14. Gordon KJ, Blobe GC. Role of transforming growth factor-beta superfamily signaling pathways in human disease. Biochim Biophys Acta. 2008;1782(4):197-28. doi:10.1016/j.bbadis.2008.01.006 . CrossRef
  15. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci U S A. 2003;100(15):8621-. doi:10.1073/pnas.1633291100 . CrossRef
  16. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI, et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology. 1993;105(6):1846-6.
  17. Booth C, Harnden P, Selby PJ, Southgate J. Towards defining roles and relationships for tenascin-C and TGFbeta-1 in the normal and neoplastic urinary bladder. J Pathol. 2002;198(3):359-8. doi:10.1002/path.1214 . CrossRef
  18. Mizukami Y, Nonomura A, Yamada T, Kurumaya H, Hayashi M, Koyasaki N, et al. Immunohistochemical demonstration of growth factors, TGF-alpha, TGF-beta, IGF-I and neu oncogene product in benign and malignant human breast tissues. Anticancer Res. 1990;10(5A):1115-6.
  19. Inoue T, Ishida T, Takenoyama M, Sugio K, Sugimachi K. The relationship between the immunodetection of transforming growth factor-beta in lung adenocarcinoma and longer survival rates. Surg Oncol. 1995;4(1):51-. CrossRef
  20. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer. 2001;91(5):964-1. CrossRef
  21. Takanami I, Tanaka F, Hashizume T, Kodaira S. Roles of the transforming growth factor beta 1 and its type I and II receptors in the development of a pulmonary adenocarcinoma: results of an immunohistochemical study. J Surg Oncol. 1997;64(4):262-. CrossRef
  22. Naslavsky N, Caplan S. EHD proteins: key conductors of endocytic transport. Trends Cell Biol. 2011;21(2):122-1. doi:10.1016/j.tcb.2010.10.003 . CrossRef
  23. Sato M, Sato K, Liou W, Pant S, Harada A, Grant BD. Regulation of endocytic recycling by C. elegans Rab35 and its regulator RME-4, a coated-pit protein. EMBO J. 2008;27(8):1183-6. CrossRef
  24. Caplan S, Naslavsky N, Hartnell LM, Lodge R, Polishchuk RS, Donaldson JG, et al. A tubular EHD1-containing compartment involved in the recycling of major histocompatibility complex class I molecules to the plasma membrane. EMBO J. 2002;21(11):2557-7. doi:10.1093/emboj/21.11.2557 . CrossRef
  25. Chen YG. Endocytic regulation of TGF-beta signaling. Cell Res. 2009;19(1):58-0. doi:10.1038/cr.2008.315 . CrossRef
  26. Bennett WP, El-Deiry WS, Rush WL, Guinee Jr DG, Freedman AN, Caporaso NE, et al. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer. Clin Cancer Res: Off J Am Assoc Cancer Res. 1998;4(6):1499-06.
  27. Meulmeester E, Ten Dijke P. The dynamic roles of TGF-beta in cancer. J Pathol. 2011;223(2):205-8. doi:10.1002/path.2785 . CrossRef
  28. Lu H, Meng Q, Wen Y, Hu J, Zhao Y, Cai L. Increased EHD1 in non-small cell lung cancer predicts poor survival. Thoracic Cancer. 2013;4(4):422-2. CrossRef
  29. Jansen FH, Krijgsveld J, van Rijswijk A, van den Bemd GJ, van den Berg MS, van Weerden WM, et al. Exosomal secretion of cytoplasmic prostate cancer xenograft-derived proteins. Molecular Cellular Proteomics: MCP. 2009;8(6):1192-05. doi:10.1074/mcp.M800443-MCP200 . CrossRef
  30. Shin J, Monti S, Aires DJ, Duvic M, Golub T, Jones DA, et al. Lesional gene expression profiling in cutaneous T-cell lymphoma reveals natural clusters associated with disease outcome. Blood. 2007;110(8):3015-7. doi:10.1182/blood-2006-12-061507 . CrossRef
  31. Wu Z-Z, Lu H-P, Chao CC-K. Identification and functional analysis of genes which confer resistance to cisplatin in tumor cells. Biochem Pharmacol. 2010;80(2):262-6. CrossRef
  32. Bierie B, Chung CH, Parker JS, Stover DG, Cheng N, Chytil A, et al. Abrogation of TGF-beta signaling enhances chemokine production and correlates with prognosis in human breast cancer. J Clin Invest. 2009;119(6):1571-2. doi:10.1172/JCI37480 . CrossRef
  
• 作者单位：Yuanyuan Gao (1)
  Yan Wang (2)
  Lichun Sun (1)
  Qingwei Meng (1)
  Li Cai (1)
  Xiaoqun Dong (3)
  
  1. The Forth Department of Medicine Oncology, Harbin Medical University Cancer Hospital, Road 150, Harbin, 150040, China
  2. The Fifth Department of Medicine Oncology, The Tumor Hospital of Harbin Medical University, Harbin, China
  3. Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, The University of Rhode Island, Pharmacy Building, 7 Greenhouse Road, Kingston, RI, 02881, USA
  
• ISSN：1423-0380

文摘

Transforming growth factor-β1 (TGFβ-1) signaling is regulated by endocytotic pathway. To clarify the prognostic value of TGFβ-1 and to verify the involvement of endocytosis in drug resistance, we examined the expression of TGFβ-1 and Eps15 homology domain 1 (EHD1) in non-small cell lung cancer (NSCLC) and its association with tumor characteristics and survival of patients with NSCLC. Expression of TGFβ-1 and EHD1 was evaluated by immunohistochemistry in paraffin sections from 105 NSCLC patients. Overall survival (OS) was analyzed by Kaplan–Meier method, log-rank test, and multivariate Cox proportional hazard regression model. Positive immunostaining of TGFβ-1 and EHD1 was detected in 52.38 and 39.05?% of NSCLC samples, respectively. In non-adjuvant chemotherapy-treated group (P--.006) and epidermal growth factor receptor (EGFR) (+) group (P--.038), patients with TGFβ-1 expression had a longer OS. EHD1 negative expression predicted a longer OS (P--.003), especially in EGFR (+) (P--.006) and adjuvant chemotherapy-treated patients (P--.003). NSCLC patients with concurrent positive TGFβ-1 and negative EHD1 (combined markers) were significantly correlated with better OS (P--.001). American Joint Committee on Cancer (AJCC) status and combined markers were independent prognostic indicators for OS (HR (95?% CI) 1.576 (1.112-.232), P--.011 and HR 0.349 (0.180-.673), P--.002, respectively). We identified concordant TGFβ-1 positive and EHD1 negative as a strong favorable prognosis factor in NSCLC. Our results may help us to select and optimize strategies for individualized therapy.